Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy
globalreutersOctober 29, 20241 Mins read 
Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million. Crescent’s lead program is a bispecific antibody for cancer that replicates the properties of a Summit Therapeutics bispecific drug that recently trounced Merck’s blockbuster med Keytruda in a pivotal head-to-head study.
The post Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy appeared first on MedCity News.
Recent Posts
Categories
Related Articles
Heat-related illnesses are preventable; here’s how
By PHIYEN NGUYEN & KRISTINA CARVALHO As we enjoy the crisp air...
WTW: There’s A Disconnect Between Employers and Employees on Wellbeing Programs
Employers are prioritizing mental wellbeing programs, but employees say they need financial...
Best hospital for Congenital Hip Dislocation Treatment
Developmental dysplasia of the hip, also known as congenital hip dislocation, is...
A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria
That is the title of my recent paper with co-authors Denise Clayton,...
Leave a comment